Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

ICR researchers identify new drug target for advanced prostate cancer patients

The team estimates that around 10% of patients have high levels of the BCL2 protein

- PMLiVE

FlyPharma Europe to return to Vienna in October

The conference will take place at Vienna AirportCity on 23 to 24 October 2024

- PMLiVE

Laying the groundwork for rare disease therapies

Addressing the challenges of convincing payers that the therapy meets an unmet need

- PMLiVE

Unlock the Future of Medical Publications—Next Week!

Dive into a comprehensive exploration of the latest trends and cutting-edge strategies in medical publication planning. Our exclusive webinar series, starting next week, offers a deep dive into the intricacies...

Impetus Digital

- PMLiVE

Innovative Trials’ CEO wins Women in Pharma Award

Kate Shaw, founder and CEO of Innovative Trials, a global clinical trial patient recruitment and retention company, won the ‘Woman in Pharma’ at the Pharma Industry Awards UK. She was...

Innovative Trials

- PMLiVE

Where did “KOLs” come from, and why do they matter?

Ever wondered where 'KOLs' came from and why they matter? Dr Alex Loveday answers those questions in this latest edition of her column.

Mednet

- PMLiVE

AstraZeneca’s Fasenra receives FDA approval to treat rare inflammatory disease EGPA

Eosinophilic granulomatosis with polyangiitis affects approximately 15,000 people in the US

- PMLiVE

Merck’s Keytruda approved by FDA as first-line malignant pleural mesothelioma treatment

More than 30,000 new cases of mesothelioma were diagnosed globally in 2022

Daiichi Sankyo logo

Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia

Approximately 18,000 cases of the blood cancer are diagnosed every year in Europe

- PMLiVE

Digital biomarkers: reinventing patient monitoring and care

By Polina Zayakina and Urs Wiedemann

- PMLiVE

Novartis’ Kisqali combination granted FDA approval for early breast cancer patients

The drug is already approved for certain cases of advanced or metastatic breast cancer

- PMLiVE

J&J’s Rybrevant combination shows positive overall survival trend in late-stage lung cancer study

Alterations in EGFR are among the most common driver mutations in NSCLC patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links